Giovanella L, Garo ML, Ceriani L, et al. - Procalcitonin (ProCT) has great potential as a substitute for calcitonin as a new standard of care in the management of medullary thyroid carcinoma (MTC). ProCT demonstrated high accuracy for MTC diagnosis and monitoring as well as favorable analytical characteristics.

• Observational studies published until May 2021 were identified from electronic databases.

• Eligible eleven studies (n = 5817 patients, 335 MTC patients) were included.

• HSROC and bivariate methods were used.

• For ProCT, pooled sensitivity, specificity, positive and negative likelihood ratios, AUC, and positive and negative predictive values were estimated to be 0.90, 1.00, 288, 0.10, 0.97, 99% and 2%, respectively.